Company

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Dr. Stefan Lang joined ImmunoPrecise Antibodies as the Chief Business Officer. He is responsible for corporate and business development initiatives, as well as corporate and product strategic planning. He holds a Dr. rer. nat. in biology from the Technical University Karlsruhe, Germany, and a diploma in biology from the University of Kassel, Germany. He started his career as a technical consultant and moved into the biotech industry in 2000.

Dr. Lang has an impressive breadth of leadership within the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development.

In his most recent role, Dr. Lang worked in an executive role at Aldevron LLC, as the Vice President of Business Development, with his main focus on corporate strategy, R&D innovation, sales and business development. Prior to Aldevron, he worked at GENOVAC, a pioneer in genetic immunization for antibody generation.

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Kari Graber serves as the Vice President of Client Relations and Project Management for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Carla Dahl is an accomplished leader with more than 20 years of strategic brand and marketing experience in the bioscience and healthcare spaces. She has a proven track record of managing major marketing initiatives for medical device launches at both start-up and multi-national companies. Prior to joining ImmunoPrecise Antibodies as the VP of Marketing in 2021, she served as the VP of Marketing at Preceptis Medical, Sr. Director Global Marketing Communication and Marketing Operations at Medtronic, Director Global Marketing at St. Jude Medical, and Director of Marketing at Cardiovascular Systems. Ms. Dahl has a distinctive history of success managing the translation of complex medical and scientific concepts into smart, market-leading brands and omni-channel strategies.

Dr. Barry Duplantis serves as Vice President of Client Relations for ImmunoPrecise Antibodies and is responsible for managing and coordinating all sales- related activities. He is a scientific entrepreneur and business development specialist with over 10 years experience in the commercial application of drug and vaccine discovery platforms. Prior to his appoint to VP of Client Relations he served as the Director of Client Relations for ImmunoPrecise Antibodies (Canada) and was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.